Dynavax CEO Eddie Gray will step down from his role on Aug. 1, 2019, as the Bay Area company undergoes restructuring to move away from immuno-oncology and prioritize the vaccine business.
Shares of Merrimack Pharmaceuticals sunk after the company announced the discontinued development of an experimental solid tumor treatment and will lay off some employees.
More than 100 Boston-area employees from two pharma companies are getting pink slips. Roche and Forma Therapeutics filed WARN notices with the state of Massachusetts.
ASLAN Pharmaceuticals is cutting staff and initiating a corporate restructuring and strategic prioritization of the company’s clinical development programs. Aduro Biotech will institute a “strategic reset” to focus on the company’s core strengths of the discovery and development of novel product candidates in the stimulator of interferon genes and a proliferation-inducing ligand pathways.
San Francisco-based uBiome laid off about 10 percent of the company’s staff and Dublin-based Theravance Biopharma cut 50 employees as part of a focus on the execution of strategic programs.
South San Francisco-based Five Prime Therapeutics announced the elimination of 41 jobs, or about 20 percent of the company’s headcount, as part of a restructuring program.
Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.
AstraZeneca filed a Worker Readjustment and Retraining Notification Act (WARN) notice with the State of Colorado, indicating plans to lay off 210 people in Boulder and Longmont.
Selecta Biosciences announced restructuring efforts that include reducing the Watertown, Mass.-based company’s workforce by 36 percent.